No Data
Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary pharmaceutical products renewed in the national medical insurance catalog
Gelonghui, November 29 - Tibet Weixinkang Pharmaceutical (603676.SH) announced that in accordance with the notice from the National Medical Insurance Administration and the Ministry of Human Resources and Social Security regarding the issuance of the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024)" (referred to as "National Medical Insurance Catalog (2024)"), the children’s multi-vitamin injection (13) from Inner Mongolia Baiyi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tibet Weixinkang Pharmaceutical Co., Ltd., will continue to be included in the "National Medical Insurance Catalog (2024)" during the contract period.
Tibet Weixinkang Pharmaceutical (603676.SH): The first repurchase of 0.1567 million shares of the company.
On November 25, 2023, Tibet Weixinkang Pharmaceutical (603676.SH) announced that on November 25, 2024, the company repurchased 156,700 shares of its stock through a centralized bidding trade method, accounting for 0.0360% of the company's total share capital. The highest fill price was 9.9 yuan per share, the lowest fill price was 9.72 yuan per share, and the total transaction amount was 1,541,919 yuan (excluding commission and other transaction fees).
Tibet Weixinkang Pharmaceutical (603676.SH): The subsidiary has withdrawn the registration application for L-Arginine (16) dipeptide (1) injection.
Glory Financial reported on November 14 that Tibet Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (referred to as "Baiyi Pharmaceutical") received the "Notice of Termination of Pharmaceutical Registration Application" issued by the National Medical Products Administration, agreeing to the withdrawal of Baiyi Pharmaceutical's registration application for Glycine (16) Dipeptide (1) Injection.
Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary pharmaceutical products pass the evaluation of consistency in quality and efficacy of generic drugs.
On November 5, Ge Longhui announced that Tibet Weixinkang Pharmaceutical (603676.SH) disclosed that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (referred to as "Baiyi Pharmaceutical") received the approval and issuance of the compound electrolyte injection (Ⅱ) "Drug Supplementary Application Approval Notice" from the National Medical Products Administration. This pharmaceutical product has passed the evaluation of generic drug quality and efficacy consistency. Compound electrolyte injection (Ⅱ) is a compound preparation composed of multiple electrolytes, suitable for the treatment of isosmotic dehydration accompanied by or expected to occur acidosis, supplementing the loss of extracellular fluid. The original research product of this pharmaceutical is "SterofundinISO" from Germany's B. Braun.
tibet weixinkang pharmaceutical (603676.SH) equity distribution in the first three quarters of 2024: 0.162 yuan per share, with equity registration on November 11th.
tibet weixinkang pharmaceutical (603676.SH) issued a notice on equity distribution for the first three quarters of 2024, and the profit distribution for this time is based on the plan...
tibet weixinkang pharmaceutical (603676.SH): Not yet repurchased
On November 4, tibet weixinkang pharmaceutical (603676.SH) announced that, as of October 31, 2024, the company has repurchased 0 shares.